** Shares of cancer drug developer MAIA Biotechnology MAIA.A rise 16.4% to $2.20
** Co says its experimental drug, THIO, helped patients with a type of lung cancer live for a median of 16.9 months, in mid-stage trial
** THIO was generally well-tolerated in patients who had received multiple previous treatments, co says
** Co says it is considering the possibility of accelerated FDA approval of THIO
** THIO gained 66.4% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。